The Predictors of Local Recurrence After Radical Cystectomy in Patients with Invasive Bladder Cancer

Key points
- Although radical cystectomy has been considered the gold standard curative treatment for invasive bladder cancer, around one third of the patients relapse and die of the disease after surgery.
- In this study, we retrospectively reviewed patients who underwent radical cystectomy for invasive bladder cancer in order to examine the association between local recurrence and distant metastasis or disease specific survival and identify independent factor predictors for local recurrence.
- We identified a study population of 146 consecutive patients treated surgically for invasive bladder cancer at our institution between 1987 and 2003.
- Local recurrence developed in 26 (17.8%) of the 146 patients at a median of 10 months (range, 1 to 73 months) after cystectomy.
Although radical cystectomy has been considered the gold standard curative treatment for invasive bladder cancer, around one third of the patients relapse and die of the disease after surgery. The main reason for cancer death in patients treated with radical cystectomy has been associated with the development of distant metastasis. Meanwhile, long-term survival after local recurrence is also extremely rare. Thus, local recurrence is thought to be as important as distant metastasis for disease specific survival. However, few studies have discussed the clinical course and natural history of local recurrence in patients with bladder cancer. The association between local recurrence and distant metastasis has also not been fully evaluated.
In this study, we retrospectively reviewed patients who underwent radical cystectomy for invasive bladder cancer in order to examine the association between local recurrence and distant metastasis or disease specific survival and identify independent factor predictors for local recurrence.
We identified a study population of 146 consecutive patients treated surgically for invasive bladder cancer at our institution between 1987 and 2003. We clarified the relationship among local recurrence, distant metastasis and disease specific survival and identified significant predictors for local recurrence.
Local recurrence developed in 26 (17.8%) of the 146 patients at a median of 10 months (range, 1 to 73 months) after cystectomy. Local recurrence was independently associated with distant metastasis in addition to the number of retrieved lymph nodes. The 2- and 5-year metastasis free rates were 86.7% and 76.5% in patients without local recurrence and 26.5% and 0% in those with local recurrence (P <0.001). The presence or absence of local recurrence and tumor grade were independent predictors of disease specific survival. The 2- and 5-year disease specific survival rates were 93.5% and 88.3% in patients without local recurrence and 55.1% and 35.4% in those with local recurrence (P <0.001). The presence of concomitant adenocarcinoma component, pathological nodal involvement, and the number of retrieved lymph nodes were independent predictors of local recurrence.
Our study revealed that local recurrence was independently associated with distant metastasis and disease specific survival. The predictive factors described above might help us select a subgroup of patients who would benefit from optimal local control, subsequently reducing distant metastasis and improving disease specific survival. There are some strategies for local control such as aggressive surgical extirpation of tissue adjacent to bladder, extended lymph node dissection and adjuvant therapy that includes a new chemotherapeutic regimen or novel molecular targeting therapy in the future. Based on our results, extensive lymph node dissection would be of benefit to reduce local recurrence.
Written by
Hiroki Ide, MD, Eiji Kikuchi, MD, Akira Miyajima, MD, Ken Nakagawa, MD, Takashi Ohigashi, MD, Jun Nakashima, MD, and Mototsugu Oya, MD, as part of Beyond the Abstract on UroToday.com.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsPET/CT Shows Clear Advantages over Conventional Staging for Patients with Locally Advanced Breast Cancer
New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic…
3 January 2013
NewsDelaying radiation therapy after hysterectomy ups risk of uterine cancer recurrence
Waiting too long after a hysterectomy to begin radiation therapy may increase the risk of uterine cancer recurrence, according to a new study from researchers at Henry Ford Hospital in Detroit. The study shows that for…
31 October 2012
NewsPretreatment PET Imaging of Lymph Nodes Predicts Recurrence in Breast Cancer Patients
Disease-free survival for invasive ductal breast cancer (IDC) patients may be easier to predict with the help of F-18-fludeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans, according to…






